SGS Papers| Volume 227, ISSUE 2, P311.e1-311.e7, August 2022

Salpingo-oophorectomy or surveillance for ovarian endometrioma in asymptomatic premenopausal women: a cost-effectiveness analysis

Published:April 27, 2022DOI:


      The lifetime risk of ovarian cancer is 1.9% among women with endometriosis compared with 1.3% among the general population. When an asymptomatic endometrioma is incidentally discovered on imaging, gynecologists must weigh the procedural complications and the potential for subsequent surgical menopause against future ovarian pathology or cancer.


      We aimed to determine if performing unilateral salpingo-oophorectomy is a more cost-effective strategy for the prevention of death than surveillance for asymptomatic endometriomas.

      Study Design

      We created a cost-effectiveness model using TreeAge Pro (TreeAge Software Inc; Williamstown, MA) with a lifetime horizon. Our hypothetical cohort included premenopausal patients with 2 ovaries who did not desire fertility. Those diagnosed with asymptomatic endometrioma underwent either unilateral salpingo-oophorectomy or surveillance (ultrasound 6–12 weeks after diagnosis, then annually). Our primary effectiveness outcome was mortality, including death from ovarian cancer or surgery and all-cause mortality related to surgical menopause (± hormone replacement therapy) if the contralateral ovary is removed. We modeled the probabilities of surgical complications, occult malignancy, development of contralateral adnexal pathology, surgical menopause, use of hormone replacement therapy, and development of ovarian cancer. The costs included surgical procedures, complications, ultrasound surveillance, hormone therapy, and treatment of ovarian cancer, with information gathered from Medicare reimbursement data and published literature. Cost-effectiveness was determined using the incremental cost-effectiveness ratio of Δ costs / Δ deaths with a willingness-to-pay threshold of $11.6 million as the value of a statistical life. Multiple 1-way sensitivity analyses were performed to evaluate model robustness.


      Our model demonstrated that unilateral salpingo-oophorectomy is associated with improved outcomes compared with surveillance, with fewer deaths (0.28% vs 1.50%) and fewer cases of ovarian cancer (0.42% vs 2.96%). However, it costs more than sonographic surveillance at $6403.43 vs $5381.39 per case of incidental endometrioma. The incremental cost-effectiveness ratio showed that unilateral salpingo-oophorectomy costs $83,773.77 per death prevented and $40,237.80 per case of ovarian cancer prevented. As both values were well below the willingness-to-pay threshold, unilateral salpingo-oophorectomy is cost-effective and is the preferred strategy. If unilateral salpingo-oophorectomy were chosen over surveillance for premenopausal patients with incidental endometriomas, 1 diagnosis of ovarian cancer would be prevented in every 40 patients and 1 death averted in every 82 patients. We performed 1-way sensitivity analyses for all input variables and determined that there were no reasonable inputs that would alter our conclusions.


      Unilateral salpingo-oophorectomy is cost-effective and is the preferred strategy compared with surveillance for the management of incidental endometrioma in a premenopausal patient not desiring fertility. It incurs fewer deaths and fewer cases of ovarian cancer with costs below the national willingness-to-pay thresholds.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Vercellini P.
        • Viganò P.
        • Buggio L.
        • et al.
        Perimenopausal management of ovarian endometriosis and associated cancer risk: when is medical or surgical treatment indicated?.
        Best Pract Res Clin Obstet Gynaecol. 2018; 51: 151-168
      1. National Cancer Institute. SEER Cancer Statistics Review 1975-2013. Available at: Accessed January 25, 2021. Bethesda, MD: National Cancer Institute; 1975–2013: 2015.

        • Saavalainen L.
        • Lassus H.
        • But A.
        • et al.
        Risk of gynecologic cancer according to the type of endometriosis.
        Obstet Gynecol. 2018; 131: 1095-1102
        • Pearce C.L.
        • Templeman C.
        • Rossing M.A.
        • et al.
        Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
        Lancet Oncol. 2012; 13: 385-394
        • Shafrir A.L.
        • Farland L.V.
        • Shah D.K.
        • et al.
        Risk for and consequences of endometriosis: a critical epidemiologic review.
        Best Pract Res Clin Obstet Gynaecol. 2018; 51: 1-15
        • Chapron C.
        • Vercellini P.
        • Barakat H.
        • Vieira M.
        • Dubuisson J.B.
        Management of ovarian endometriomas.
        Hum Reprod Update. 2002; 8: 591-597
        • As-Sanie S.
        • Black R.
        • Giudice L.C.
        • et al.
        Assessing research gaps and unmet needs in endometriosis.
        Am J Obstet Gynecol. 2019; 221: 86-94
        • Anglesio M.S.
        • Yong P.J.
        Endometriosis-associated ovarian cancers.
        Clin Obstet Gynecol. 2017; 60: 711-727
        • Mallen A.
        • Soong T.R.
        • Townsend M.K.
        • Wenham R.M.
        • Crum C.P.
        • Tworoger S.S.
        Surgical prevention strategies in ovarian cancer.
        Gynecol Oncol. 2018; 151: 166-175
        • Torre L.A.
        • Trabert B.
        • DeSantis C.E.
        • et al.
        Ovarian cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 284-296
        • Rossing M.A.
        • Cushing-Haugen K.L.
        • Wicklund K.G.
        • Doherty J.A.
        • Weiss N.S.
        Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery.
        Cancer Causes Control. 2008; 19: 1357-1364
        • Alio L.
        • Angioni S.
        • Arena S.
        • et al.
        Endometriosis: seeking optimal management in women approaching menopause.
        Climacteric. 2019; 22: 329-338
        • Melin A.S.
        • Lundholm C.
        • Malki N.
        • Swahn M.L.
        • Sparèn P.
        • Bergqvist A.
        Hormonal and surgical treatments for endometriosis and risk of epithelial ovarian cancer.
        Acta Obstet Gynecol Scand. 2013; 92: 546-554
        • Parker W.H.
        • Feskanich D.
        • Broder M.S.
        • et al.
        Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study.
        Obstet Gynecol. 2013; 121: 709-716
        • Orlando M.S.
        • Yao M.
        • Chang O.H.
        • et al.
        Perioperative outcomes in a nationwide sample of patients undergoing surgical treatment of ovarian endometriomas.
        Fertil Steril. 2022; 117: 444-453
        • Kuo H.H.
        • Huang C.Y.
        • Ueng S.H.
        • Huang K.G.
        • Lee C.L.
        • Yen C.F.
        Unexpected epithelial ovarian cancers arising from presumed endometrioma: a 10-year retrospective analysis.
        Taiwan J Obstet Gynecol. 2017; 56: 55-61
        • Nishida M.
        • Watanabe K.
        • Sato N.
        • Ichikawa Y.
        Malignant transformation of ovarian endometriosis.
        Gynecol Obstet Investig. 2000; 50: 18-25
        • Jang J.
        • Arora N.
        • Kwon J.S.
        • Hanley G.E.
        Hormone therapy use after premature surgical menopause based on prescription records: a population-based study.
        J Obstet Gynaecol Can. 2020; 42: 1511-1517
        • Rice M.S.
        • Hankinson S.E.
        • Tworoger S.S.
        Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses’ Health Studies.
        Fertil Steril. 2014; 102: 192-198.e3
        • Chan J.K.
        • Urban R.
        • Capra A.M.
        • et al.
        Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy.
        Obstet Gynecol. 2014; 123: 65-72
        • Froyman W.
        • Landolfo C.
        • De Cock B.
        • et al.
        Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study.
        Lancet Oncol. 2019; 20: 448-458
        • Hidari T.
        • Hirata T.
        • Arakawa T.
        • et al.
        Contralateral ovarian endometrioma recurrence after unilateral salpingo-oophorectomy.
        BMC Womens Health. 2019; 19: 59
        • Heintz A.
        • Odicino F.
        • Maisonneuve P.
        • et al.
        Carcinoma of the ovary.
        Int J Gynaecol Obstet. 2006; 95: S161-S192
        • Parker W.H.
        • Broder M.S.
        • Chang E.
        • et al.
        Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study.
        Obstet Gynecol. 2009; 113: 1027-1037
        • Cadish L.A.
        • Shepherd J.P.
        • Barber E.L.
        • Ridgeway B.
        Risks and benefits of opportunistic salpingectomy during vaginal hysterectomy: a decision analysis.
        Am J Obstet Gynecol. 2017; 217: 603.e1-603.e6
        • Centers for Medicare and Medicaid Services
        Physician fee schedule search. 2021.
        (Available at:)
        • GoodRx
        Estrace prices, coupons & savings tips.
        (Available at:)
        Date: 2021
        Date accessed: August 30, 2021
        • Urban R.R.
        • He H.
        • Alfonso-Cristancho R.
        • Hardesty M.M.
        • Goff B.A.
        The cost of initial care for medicare patients with advanced ovarian cancer.
        J Natl Compr Canc Netw. 2016; 14: 429-437
      2. ACOG Practice Bulletin no. 141: management of menopausal symptoms.
        Obstet Gynecol. 2014; 123: 202-216
        • United States Department of Transportation
        Departmental guidance on valuation of a statistical life in economic analysis.
        (Available at:)
        • Exacoustos C.
        • De Felice G.
        • Pizzo A.
        • et al.
        Isolated ovarian endometrioma: a history Between myth and reality.
        J Minim Invasive Gynecol. 2018; 25: 884-891
        • The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
        The 2017 hormone therapy position statement of the North American Menopause Society.
        Menopause. 2017; 24: 728-753
        • Falcone T.
        • Flyckt R.
        Clinical management of endometriosis.
        Obstet Gynecol. 2018; 131: 557-571
      3. Practice Bulletin no. 114: management of endometriosis.
        Obstet Gynecol. 2010; 116: 223-236
        • Gemmell L.C.
        • Webster K.E.
        • Kirtley S.
        • Vincent K.
        • Zondervan K.T.
        • Becker C.M.
        The management of menopause in women with a history of endometriosis: a systematic review.
        Hum Reprod Update. 2017; 23: 481-500
        • Thomsen L.H.
        • Schnack T.H.
        • Buchardi K.
        • et al.
        Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review.
        Acta Obstet Gynecol Scand. 2017; 96: 761-778
        • Falconer H.
        • Yin L.
        • Grönberg H.
        • Altman D.
        Ovarian cancer risk after salpingectomy: a nationwide population-based study.
        J Natl Cancer Inst. 2015; 107: 1-6